The anti-leukemic effects of 17C7 and 20F2 were confirmed by the reduction of human CD45+CD33+ leukemia cells in peripheral blood (PB) and BM of NSG-recipients following treatments (Fig. 7c and Supplementary Fig. 7e). This evidence concerns the gene CD33 and leukemia.